A recent article published in Future Microbiology discussed that sarecycline – a novel, narrow- spectrum, once-daily tetracycline-derived oral antibiotic, has been FDA-approved to be taken with or without food for moderate-to-severe acne vulgaris—for children and adolescents, 9 years of age and older. The authors elaborated that sarecycline possesses anti-inflammatory properties and potent activity against Gram-positive bacteria, including activity against multiple strains of Cutibacterium acnes. This agent also exhibits minimal activity against enteric aerobic Gram-negative bacteria. Sarecycline has been investigated for chest and back acne—the findings showed significant reduction in inflammatory lesions at week 12 at 1.5 mg/kg/day of sarecycline with statistically significant improvement observed as early as the third week. Furthermore, there were no reports of phototoxicity, dizziness, pseudotumor cerebri or lupus. Moreover, the side effects were minimal and minor like nausea and vaginal candidiasis in the pivotal Phase III studies.

Source: Future Microbiology. 2019 Sep; 14(14): 1235–1242.